ArticleCPT: pharmacometrics & systems pharmacology2025
Vancomycin population pharmacokinetic models: Uncovering pharmacodynamic divergence amid clinicobiological resemblance.
Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Model-informed vancomycin precision dosing by population pharmacokinetics combined with machine learning algorithms.British journal of clinical pharmacology · 2026Article
- Model Ensembling and Machine Learning Approaches to Predict the First Dose of Amoxicillin in Intensive Care.CPT: pharmacometrics & systems pharmacology · 2026Article
- External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients.CPT: pharmacometrics & systems pharmacology · 2026Observational
- Intra-Individual Variability of Vancomycin Trough Concentrations Before and After Implementation of a Standardized Operating Procedure in Orthopedic Inpatients.Antibiotics (Basel, Switzerland) · 2026Article
- Vancomycin target attainment improved following population pharmacokinetic model switch: a large-scale quasi-experimental study of precision dosing.JAC-antimicrobial resistance · 2026Article
- Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD.CPT: pharmacometrics & systems pharmacology · 2026Article
- Machine Learning-Based Model Selection and Averaging Outperform Single-Model Approaches for a Priori Vancomycin Precision Dosing.CPT: pharmacometrics & systems pharmacology · 2025Article
- Vancomycin population pharmacokinetic models: Uncovering pharmacodynamic divergence amid clinicobiological resemblance.CPT: pharmacometrics & systems pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vancomycin is an antibiotic used for severe infections. To ensure microbiological efficacy, a ratio of AUC/MIC ≥400 is recommended. However, there is significant interindividual variability in its pharmacokinetic parameters, necessitating therapeutic drug monitoring to adjust dosing regimens and ensure efficacy while avoiding toxicity. Population pharmacokinetic (PopPK) models enable dose personalization, but the challenge lies in the choice of the model to use among the multitude of models in the literature. We compared 18 PopPK models created from populations with the same sociodemographic and clinicobiological characteristics. Simulations were performed for a 47 years old man, weighing 70 kg, with an albumin level of 35.5 g/L, a creatinine clearance of 100 mL/min, an eGFR of 106 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.